ICOTYDE™
(icotrokinra)
ICOTYDE™ (icotrokinra)
Icotyde - pivotal clinical trial publications
ICONIC - LEAD
Bissonnette R, Soung J, Hebert AA, et al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393:1784-1795.
ICONIC - TOTAL
Gooderham M, Lain E, Bissonnette R, et al. Targeted oral peptide icotrokinra for psoriasis involving high-impact sites. NEJM Evid. 2025;4(12).
ICONIC - ADVANCE
Gold L, Armstrong A, Bissonnette R, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phases 3, randomized, placebo-controlled and active-comparator-controlled trials. Lancet. 2025; 406: 1363-1374.